Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2.
about
High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial.Albumin therapy enhances collateral perfusion after laser-induced middle cerebral artery branch occlusion: a laser speckle contrast flow studyUnderstanding the role of prostaglandin E2 in regulating human platelet activity in health and diseaseImpaired leptomeningeal collateral flow contributes to the poor outcome following experimental stroke in the Type 2 diabetic mice.Symptomatic intracranial hemorrhage in the ALIAS Multicenter Trial: relationship to endovascular thrombolytic therapy.Investigational therapies for ischemic stroke: neuroprotection and neurorecovery.Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.Plasma albumin and platelet function: relevance to atherogenesis and thrombosis.Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.Prognostic nutritional index predicts clinical outcome in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.Value of albumin-globulin ratio as a predictor of all-cause mortality after non-ST elevation myocardial infarction.Original Article: Albumin Prevents TxB, Formation from Thrombin-stimulated Human Platelets by Sequestering the Liberated Arachidonic Acid in the Extracellular Space.Preprocedural Albumin Levels and Risk of In-Stent Restenosis After Coronary Stenting With Bare-Metal Stent.Serum albumin levels on admission are associated with angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.
P2860
Q30572344-3324B969-DE30-4501-B996-C31486520FBAQ34332600-1F0C430A-5D7D-414B-AE92-0EEA7C637498Q34480894-04737917-3B28-47BC-893D-D5BFA993099CQ35142897-2F365F88-D181-4E16-B09D-F969550EF1E4Q35611490-C891E2A0-DB0D-4B0B-9AE4-7BE26AA798B4Q35648103-B77836A2-17E9-4333-B1F0-99E59DD8389BQ37588694-D2510E79-BC65-4E8B-959F-010A392B5A11Q37806205-5CF31BD2-D316-4953-AA8D-0E1AAE591630Q41015991-3BD9A7A9-3829-4375-84C0-F06F92BC2F1CQ41823907-E5BA6046-8A7D-4934-BBFD-6221560D4631Q44425744-9016C691-B0A6-463A-9798-6AE48CE73A2CQ47776698-C9AE6CF1-2317-4812-8F3C-B3588759D85BQ51821058-45879BFD-8EBC-4C29-8FB8-7638F16F043CQ54366922-C6B792D0-A2A2-4A63-A8E9-2394C43DB151
P2860
Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
1984年论文
@zh
1984年论文
@zh-cn
name
Serum albumin enhances the imp ...... formation of prostaglandin D2.
@en
Serum albumin enhances the imp ...... formation of prostaglandin D2.
@nl
type
label
Serum albumin enhances the imp ...... formation of prostaglandin D2.
@en
Serum albumin enhances the imp ...... formation of prostaglandin D2.
@nl
prefLabel
Serum albumin enhances the imp ...... formation of prostaglandin D2.
@en
Serum albumin enhances the imp ...... formation of prostaglandin D2.
@nl
P1476
Serum albumin enhances the imp ...... formation of prostaglandin D2.
@en
P2093
Huybrechts E
Vermylen J
P304
P356
10.1016/0006-2952(84)90577-X
P407
P577
1984-07-01T00:00:00Z